{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:46:05Z","timestamp":1790077565880,"version":"4.0.1"},"reference-count":50,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.<\/ns4:p>","DOI":"10.12688\/f1000research.14122.1","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T10:45:11Z","timestamp":1532515511000},"page":"1136","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Current overview and treatment of mantle cell lymphoma"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9994-8579","authenticated-orcid":false,"given":"Michael","family":"Schieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1394-402","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1- mantle cell lymphoma.","volume":"121","author":"I Salaverria","year":"2013","journal-title":"Blood."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1555-62","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.","volume":"94","author":"A Mozos","year":"2009","journal-title":"Haematologica."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"2175-85","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.","volume":"121","author":"M Vegliante","year":"2013","journal-title":"Blood."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"5307-16","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.","volume":"72","author":"A Navarro","year":"2012","journal-title":"Cancer Res."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"2489-95","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma.","volume":"28","author":"P Abrisqueta","year":"2017","journal-title":"Ann Oncol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1209-13","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma.","volume":"27","author":"P Martin","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1338-46","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.","volume":"32","author":"E Hoster","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1386-94","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.","volume":"34","author":"E Hoster","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"417-20","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.","volume":"131","author":"S Aukema","year":"2018","journal-title":"Blood."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1785-91","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype.","volume":"15","author":"M Bernard","year":"2001","journal-title":"Leukemia."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"e61-e67","DOI":"10.1016\/j.clml.2017.10.006","article-title":"VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.","volume":"18","author":"J Chang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1665-73","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).","volume":"123","author":"J Chang","year":"2014","journal-title":"Blood."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"7013-23","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"J Romaguera","year":"2005","journal-title":"J Clin Oncol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"565-75","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.","volume":"388","author":"O Hermine","year":"2016","journal-title":"Lancet."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2687-93","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"C Geisler","year":"2008","journal-title":"Blood."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"355-62","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.","volume":"158","author":"C Geisler","year":"2012","journal-title":"Br J Haematol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2677-84","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"M Dreyling","year":"2005","journal-title":"Blood."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"428-35","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.","volume":"23","author":"A Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1861-9","DOI":"10.1016\/j.bbmt.2017.07.006","article-title":"Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.","volume":"23","author":"M Mei","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"4365-70","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.","volume":"27","author":"N Andersen","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1250-60","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.","volume":"377","author":"S Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"520-31","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"H Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2944-52","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.","volume":"123","author":"I Flinn","year":"2014","journal-title":"Blood."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1203-10","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"M Rummel","year":"2013","journal-title":"Lancet."},{"key":"ref-25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V124.21.148.148","article-title":"Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group.","volume":"124","author":"R Gressin","year":"2014","journal-title":"Blood."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"e15-e23","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.","volume":"4","author":"C Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1835-44","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.","volume":"373","author":"J Ruan","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1814-20","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.","volume":"128","author":"A Albertsson-Lindblad","year":"2016","journal-title":"Blood."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"944-53","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.","volume":"372","author":"T Robak","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"4867-74","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"R Fisher","year":"2006","journal-title":"J Clin Oncol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"496-503","DOI":"10.1111\/bjh.13456","article-title":"Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.","volume":"170","author":"A Goy","year":"2015","journal-title":"Br J Haematol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"507-16","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"M Wang","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"770-8","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.","volume":"387","author":"M Dreyling","year":"2016","journal-title":"Lancet."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"3822-9","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.","volume":"27","author":"G Hess","year":"2009","journal-title":"J Clin Oncol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"3688-95","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.","volume":"31","author":"A Goy","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"319-31","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial.","volume":"17","author":"M Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"659-67","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.","volume":"391","author":"M Wang","year":"2018","journal-title":"Lancet."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1211-23","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.","volume":"378","author":"C Tam","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"826-33","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.","volume":"35","author":"M Davids","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1587-97","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO).","volume":"93","author":"W Kr\u00fcger","year":"2014","journal-title":"Ann Hematol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1184-90","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.","volume":"51","author":"B Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"87-92","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma.","volume":"20","author":"R Rahal","year":"2014","journal-title":"Nat Med."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"82-92","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma.","volume":"128","author":"N Saba","year":"2016","journal-title":"Blood."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"343-52","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.","volume":"32","author":"B Sun","year":"2018","journal-title":"Leukemia."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"1565-74","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.","volume":"126","author":"B Sun","year":"2015","journal-title":"Blood."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"34-38.e2","DOI":"10.1016\/j.exphem.2017.01.001","article-title":"Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.","volume":"49","author":"E Mostaghel","year":"2017","journal-title":"Exp Hematol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"14-9","DOI":"10.1016\/j.critrevonc.2016.08.008","article-title":"ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma.","volume":"107","author":"M Ahmed","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1963-71","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.","volume":"119","author":"R Kridel","year":"2012","journal-title":"Blood."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1903-10","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.","volume":"130","author":"C Eskelund","year":"2017","journal-title":"Blood."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"629-35","DOI":"10.1007\/s00432-017-2529-9","article-title":"Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.","volume":"144","author":"A Augustin","year":"2018","journal-title":"J Cancer Res Clin Oncol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T04:02:47Z","timestamp":1571630567000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":50,"URL":"https:\/\/doi.org\/10.12688\/f1000research.14122.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.15360.r36191","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.15360.r36190","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.15360.r36189","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.15360.r36191, Vincent Ribrag, Chairman of DITEP multidisciplinary committee and Chief of Molecular therapeutics in hematological early drug development, Gustave Roussy Comprehensive Cancer Center, Villejuif, France, 25 Jul 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1#referee-response-36191","order":0,"name":"referee-response-36191","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.15360.r36190, Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA, 25 Jul 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1#referee-response-36190","order":1,"name":"referee-response-36190","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.15360.r36189, Andre H. Goy, Lymphoma Division, John Theurer Cancer Center, Hackensack, New Jersey, USA, 25 Jul 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1136\/v1#referee-response-36189","order":2,"name":"referee-response-36189","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}